Status:
RECRUITING
Prostate Cancer Burden and Heterogeneity Evaluation Towards Liquid Biopsy: a Correlation Study to 18FDCFPyL PET and Patients Outcome
Lead Sponsor:
Institut Claudius Regaud
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
NA
Brief Summary
This is a prospective, monocentric, proof of concept study aims to identify in prostate cancer patients, a potential relationship between CTC-PSMA positivity and 18F-PET-PSMA results as well as patien...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologically confirmed adenocarcinoma of the prostate
- Indication for 18F-PET-PSMA imaging
- Signed written informed consent
- Patient able to participate and willing to give informed consent prior performance of any study-related procedures and to comply with the study protocol
- Patient affiliated to a Social Health Insurance in France.
Exclusion
- Patients with a contraindication to 18F-PET-PSMA
- Patient with an established neuro endocrine prostate cancer
- Concurrent malignancy known to express a significant amount of PSMA (renal cancer, salivary gland tumors)
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure
- Patient who has forfeited his freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Key Trial Info
Start Date :
October 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06917781
Start Date
October 28 2025
End Date
October 1 2028
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
IUCT-O
Toulouse, France